European Medicines Agency updates on ongoing safety review of sibutramine: Weight-loss medicine assessed over cardiovascular concerns

View source ↗

Summary

The EMA provides updates on ongoing safety review of sibutramine, a weight-loss medicine, focusing on cardiovascular concerns.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Sibutramine (sibutramine)